Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intra-Cellular Therapies Inc ITCI

Healthcare Psychedelics
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical... see more

Recent & Breaking News (NDAQ:ITCI)

Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of Neuropsychopharmacology

GlobeNewswire December 7, 2017

Intra-Cellular Therapies to Participate at the 29th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 27, 2017

Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia

GlobeNewswire November 20, 2017

Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for Neuroscience (SfN) Annual Meeting

GlobeNewswire November 14, 2017

Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr. Andrew Satlin as Executive Vice President and Chief Medical Officer

GlobeNewswire November 13, 2017

Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2017

Intra-Cellular Therapies, Inc. to Host Earnings Call

Accesswire November 8, 2017

Intra-Cellular Therapies to Host Third Quarter 2017 Financial Results Conference Call and Webcast

GlobeNewswire November 3, 2017

Intra-Cellular Therapies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock

GlobeNewswire October 5, 2017

Intra-Cellular Therapies Announces Commencement of Enrollment of a Clinical Trial Evaluating ITI-214 in Patients with Parkinson’s Disease

GlobeNewswire October 3, 2017

Intra-Cellular Therapies Announces Closing of $150 Million Public Offering of Common Stock

GlobeNewswire October 2, 2017

Intra-Cellular Therapies Prices $150 Million Public Offering of Common Stock

GlobeNewswire September 27, 2017

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

GlobeNewswire September 26, 2017

Intra-Cellular Therapies to Participate at Upcoming Investor Conferences

GlobeNewswire September 18, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  September 7, 2017

Intra-Cellular Therapies Announces Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia

GlobeNewswire September 7, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  August 30, 2017

Stock Performance Review on Biotech Industry -- Exelixis, Geron, Inovio Pharma, and Intra Cellular Therapies

PR Newswire August 28, 2017

Mid-Afternoon Market Update: Crude Oil Up Over 1%; Express Shares Rise After Strong Q2 Results

Benzinga.com  August 23, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  August 23, 2017